Grants and Contributions:
Title:
Covid-19 Response: DPX-COVID-19: Neutralizing-epitope Based Synthetic Vaccine with Potential for Large Scale Production
Agreement Number:
948901
Agreement Value:
$636,596.00
Agreement Date:
Apr 1, 2020 - Dec 31, 2020
Description:
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Dartmouth, Nova Scotia, CA B3B 2C4
Reference Number:
172-2020-2021-Q1-948901
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
864736772
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days. The total amended value is 258,357 dollars.
Amendment Date
Jul 28, 2020
Recipient's Legal Name:
ImmunoVaccine Technologies Inc.
Federal Riding Name:
Dartmouth--Cole Harbour
Federal Riding Number:
12004
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: